Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXian ZhangPLPeihua Lu

Discussion

Loading...

Member takes

Overview

Phase I/II trials show CD7 CAR-T therapy achieves remission in CNS T-cell lymphoma, indicating manageable safety.

Key Points

  • To evaluate the efficacy and safety of CD7-targeted CAR-T cell therapy in patients with CNS involvement of relapsed/refractory T-cell lymphoblastic leukemia/lymphoma.
  • Phase I/II clinical trials involving 30 patients with CNS involvement
  • Collection of peripheral blood mononuclear cells via leukapheresis
  • Administration of fludarabine and cyclophosphamide conditioning regimens before NS7 CAR-T infusion
  • Monitoring of CAR-T cell proliferation and clearance in cerebrospinal fluid using flow cytometry
  • Assessment of safety and efficacy outcomes post-infusion.
  • 100% of patients achieved complete remission in cerebrospinal fluid after CD7 CAR-T infusion
  • 89.5% shown minimal residual disease negative complete remission in bone marrow
  • 1-year overall survival rate was 83% and progression-free survival was 52.8%
  • 90% of patients experienced mild cytokine release syndrome, with manageable cases of neurotoxicity.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d47dhttps://doi.org/10.1182/blood-2025-1039
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study2025
  2. 2Efficacy, Safety, and Kinetics of Naturally Selected Anti‐ CD7 CAR ‐T Cell Therapy in T‐ ALL / LBL With CNS Leukemia2026
  3. 3Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  4. 4CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study2025
  5. 5Anti-CD7 CAR T-cell therapy for ultra-high-risk relapsed/refractory T-ALL/lbl: Insights into lineage switch and consolidation strategies2025